Therefore, these particular STATs have emerged as pharmacological targets for cancer therapy, and the development of novel STAT3/5 inhibitors is of considerable clinical interest for treating breast cancer, glioma, and leukemia [9–11]. The gene discussed is STAT3; the disease is leukemia.